In cost-effectiveness analysis, the incremental cost-effectiveness ratio is used to measure economic efficiency of a new intervention, relative to an existing one. However, costs and effects are seldom known with certainty. Uncertainty arises from two main sources: uncertainty regarding correct values of intervention-related parameters and uncertainty associated with sampling variation. Recently, attention has focused on Bayesian techniques for quantifying uncertainty. We computed the Bayesian-based 95% credible interval estimates of the incremental cost-effectiveness ratio of several related HIV prevention interventions and compared these results with univariate sensitivity analyses. The conclusions were comparable, even though the probabilistic technique provided additional information.
Get full access to this article
View all access options for this article.
References
1.
Abramson, P. R., and B. Rothchild. 1988. Sex, drugs and matrices: Mathematical prediction of HIV infection. Journal of Sex Research25:106-122.
2.
Alioum, A., V. Leroy, D. Commemges, F. Dabis, and R. Salamon. 1998. Effect of gender, age, transmission category, and anti retroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Epidemiology9:605-612.
3.
Barlow, D., G. Daker-White, and B. Band. 1997. Assortative sexual mixing in a heterosexual clinic population—A limiting factor in HIV spread?AIDS11:1039-1044.
4.
Bedimo, A. L., S. D. Pinkerton, D. A. Cohen, B. Gray, and T. A. Farley. 2001. Cost-savings of a condom social marketing program. Under review.
5.
Bell, D. C., and R. A. Trevino. 1999. Modeling HIV risk. Acquired Immune Deficiency Syndrome22:280-287.
6.
Black, W. C.1990. The CE plane: A graphic representation of cost-effectiveness. Medical Decision Making10:147, 212-214.
7.
Brookmeyer, R., and M. H. Gail. 1994. AIDS epidemiology: A quantitative approach. New York: Oxford University Press.
8.
Briggs, A.1995. Handling uncertainty in the results of economic evaluation. OHE Briefing no. 32. Office of Health Economics32:1-12.
9.
Briggs, A., and P. Fenn. 1998. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Economics7:723-740.
10.
Brown, M. L., and L. Fintor. 1993. Cost-effectiveness of breast cancer screening: Preliminary results of a systematic review of the literature. Breast Cancer Resource Treatment8:113-118.
11.
Carlin, B. P., and T. A. Louis. 1998. Bayes and empirical Bayes methods for data analysis. Boca Raton, FL: Chapman & Hall: CRC Press LLC.
12.
Chesson, H. W., and S. D. Pinkerton. Forthcoming. STDs and the increased risk for HIV transmission: Implications for cost-effectiveness analyses of STD prevention interventions. Journal of Acquired Immune Deficiency Syndromes24:48-54.
13.
Critchfield, G. C., and K. E. Willard. 1986. Probabilistic analysis of decision trees using Monte Carlo simulation. Medical Decision Making6:85-92.
14.
Critchfield, G. C., K. E. Willard, and D. P. Connelly. 1986. Probabilistic sensitivity analysis methods for general decision models. Computers & Biomedical Research19:254-265.
15.
Doubilet, P., C. B. Begg, M. C. Weinstein, P. Braun, and B. J. McNeil. 1985. Probabilistic sensitivity analysis using Monte Carlo simulation: A practical approach. Medical Decision Making5:157-177.
16.
Downs, A. M., I. de Vincenzi, and European Study Group in Heterosexual Transmission of HIV. 1996. Probability of heterosexual transmission of HIV: Relationship to the number of unprotected sexual contacts. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology11:388-395.
17.
Drummond, M. F., B. J. O'Brien, G. L. Stoddart, and G. W. Torrance. 1997. Methods for the economic evaluation of health care programmes. New York: Oxford University Press.
18.
Freedberg, K. A., J. A. Scharfstein, G. R. Searge, E. Losina, M. C. Weinstein, D. E. Craven, and A. D. Paltiel. 1998. The cost-effectiveness of preventing AIDS-related opportunistic infections. Journal of the American Medical Association279:130-136.
19.
Garnett, G. P., and A. M. Johnson. 1997. Coining a new term in epidemiology: Concurrency and HIV. AIDS11:681-683.
20.
Gold, M. R., J. E. Siegel, L. B. Russel, and M. C. Weinstein. 1996. Cost-effectiveness in health and medicine. New York: Oxford University Press.
21.
Heitjan, D. F., A. J. Moskowitz, and W. Whang. 1999. Bayesian estimates of cost-effectiveness ratios from clinical trials. Health Economics8:191-201.
22.
Holmberg, S. D.1996. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. American Journal of Public Health86:642-654.
23.
Holtgrave, D. R., and J. A. Kelly. 1996. Preventing HIV/AIDS among high-risk urban women: The cost-effectiveness of a behavioral group intervention. American Journal of Public Health86:1442-1445.
24.
Holtgrave, D. R., and J. A. Kelly. 1997. The cost-effectiveness of an HIV prevention intervention for gay men. AIDS and Behavior1:173-180.
25.
Holtgrave, D. R., and S. D. Pinkerton. 1997. Updates of cost of illness and quality of life estimates for use in economic evaluation of HIV prevention programs. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology16:54-62.
26.
Iversen, G. R.1984. Bayesian statistical inference. Series: Quantitative applications in the social sciences. Newbury Park, CA: Sage.
27.
Johnson-Masotti, A. P., S. D. Pinkerton, J. A. Kelly, and L. Y. Stevenson. 2000. Cost-effectiveness of an HIV risk reduction intervention for adults with severe mental illness. AIDS Care12:321-332.
28.
Kaplan, E. H. 1989. Can bad models suggest good policy? Sexual mixing and the AIDS epidemic. Journal of Sex Research26:301-314.
29.
Kaplan, E. H.1990. Modeling HIV infectivity: Must sex acts be counted?Journal of Acquired Immune Deficiency Syndromes3:55-61.
30.
Laska, E. M., M. Meisner, and C. Siegel. 1997. Statistical inference for cost-effectiveness ratios. Health Economics6:229-242.
31.
Laupacis, A., D. Fenny, A. S. Detsky, and P. X. Tugwell. 1993. Tentative guidelines for using clinical and economic evaluations revisited. Canadian Medical Association Journal148:927-929.
32.
Mastro, T. D., and I. de Vincenzi. 1996. Probabilities of sexual HIV-1 transmission. AIDS10 (suppl. A): S75-82.
33.
Morris, M., and M. Kretzschmar. 1997. Concurrent partnerships and the spread of HIV. AIDS11:641-648.
34.
O'Brien, B. J., M. F. Drummond, R. J. Labelle, and A. Willan. 1994. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Medical Care32:150-163.
35.
O'Brien, B. J., and M. J. Sculpher. 2000. Building uncertainty into cost-effectiveness ranking portfolio risk-return tradeoffs and implications for decision rules. Medical Care38:460-468.
36.
O'Hagan, A., J. W. Stevens, and J. Montmartin. 2000a. Bayesian cost effectiveness analysis from clinical trial data [Online]. Statistics in Medicine. Available from http://www.shef.ac.uk/∼st1ao/pub.html.
37.
O'Hagan, A., J. W. Stevens, and J. Montmartin. 2000b. Inference for the C/E acceptability curve and C/E ratio. Pharmacoeconomics17:339-349.
38.
Owens, D. K., R. F. Nease, and R. Harris. 1993. Use of cost-effectiveness and value of information analysis to customize guidelines for specific clinical practice settings (abstract). Medical Decision Making13:395-395.
39.
Paltiel, A. D., and A. A. Stinnett. 1998. Resource allocation and the funding of HIV prevention. Handbook of Economic Evaluation of HIV Prevention Programs, edited by D. R. Holtgrave, 135-149. New York: Plenum.
40.
Pinkerton, S. D., and P. R. Abramson. 1997. Effectiveness of condoms in preventing HIV transmission. Social Science and Medicine44:1303-1312.
41.
Pinkerton, S. D., and P. R. Abramson. 1998. The Bernoulli-process model of HIV transmission: Applications and implications. Handbook of economic evaluation of HIV prevention programs, edited by D. R. Holtgrave, 13-32. New York: Plenum.
42.
Pinkerton, S. D., P. R. Abramson, S. C. Kalichman, C. L. Catz, and A. P. Johnson-Masotti. 2000. Secondary HIV transmission rates in a mixed-gender sample. International Journal of STD & AIDS11:38-44.
43.
Pinkerton, S. D., and D. R. Holtgrave. 1998. Assessing the cost-effectiveness of HIV prevention interventions: A primer. Handbook of economic evaluation of HIV prevention programs, edited by D. R. Holtgrave, 34-41. New York: Plenum.
44.
Pinkerton, S. D., D. R. Holtgrave, W. J. DiFranceisco, S. Seeman, S. L. Coyle, and A. P. Johnson-Masotti. Cost-threshold analyses of the National AIDS Demonstration Research HIV prevention interventions. AIDS, 14:1257-1268.
45.
Pinkerton, S. D., D. R. Holtgrave, W. J. DiFranceisco, L. Y. Stevenson, and J. A. Kelly. 1998. Cost-effectiveness of a community-level HIV risk reduction intervention. American Journal of Public Health88:1239-1242.
46.
Pinkerton, S. D., D. R. Holtgrave, and J. B. Jemmott. 2000Economic analysis of an HIV risk reduction intervention for male African American adolescents. Journal of Acquired Immune Deficiency Syndromes,25:164-172.
47.
Pinkerton, S. D., D. R. Holtgrave, and L. C. Leviton. 1998. Model-based evaluation of HIV prevention interventions. Evaluation Review22:155-174.
48.
Pinkerton, S. D., D. R. Holtgrave, and R. O. Valdiserri. 1997. Cost-effectiveness of HIV-prevention skills training for men who have sex with men. AIDS11:347-357.
49.
Rehle, T. M., T. J. Saidel, S. E. Hassig, P. D. Bouey, E. M. Gaillard, and D. C. Sokal. 1998. AVERT: A user-friendly model to estimate the impact of HIV/sexually transmitted disease prevention interventions on HIV transmission. AIDS12 (suppl. 2): S27-35.
50.
Schneider, D. J., E. L. Taylor, L. M. Prater, and M. P. Wright. 1991. Risk assessment for HIV infection: Validation study of a computer-assisted preliminary screen. AIDS Education and Prevention3:215-229.
51.
Sonnenberg, F. A., and J. R. Beck. 1993. Markov models in medical decision making: A practical guide. Medical Decision Making13:322-338.
52.
Stinnett, A. A., and J. Mullahy. 1998. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making18 (suppl.): S68-80.
53.
Tambour, M., N. Zethraeus, and M. Johannesson. 1998. A note on confidence intervals in cost-effectiveness analysis. International Journal of Technology Assessments in Health Care14:467-471.
54.
Tolley, G. L., D. Kenkel, and R. Fabian. 1994. Valuing health for policy: An economic approach. Chicago: University of Chicago Press.
55.
Van Hout, B. A., M. J. Al, G. S. Gordon, and F.F.H. Rutten. 1994. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics3:309-319.
56.
Wakker, P., and M. P. Klaassen. 1995. Confidence intervals for cost-effectiveness ratios. Health Economics4:373-381.
57.
Weinstein, M. C., J. D. Graham, J. E. Siegel, and H. V. Fineberg. 1989. Cost-effectiveness analysis of AIDS preventions programs: Concepts, complications, and illustrations. AIDS: Sexual behavior and intravenous drug use, edited by C. F. Turner, H. G. Miller, and L. E. Moses, 471-499. Washington, DC: National Academy Press.
58.
Willan, A. R., and B. J. O'Brien. 1996. Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem. Health Economics5:297-305.
59.
Willard, K. E., and G. C. Critchfield. 1986. Probabilistic analysis of decision trees using symbolic algebra. Medical Decision Making6:93-100.
